Report Screener | Stock Screener | Bond Screener | Fund Screener

Report Search Results (Showing 1 to 16 of 16)As of 22-Nov-2009
New Screen 

All Reports | Brokerage Reports | Independent Reports
Release
Date [down]		 Contributor Author Title Pages Price StarMine Author Rating More Info
EPS Accuracy * Portfolio Return **
6-Nov-09Feltl & CompanyErnest W. AndbergROCM- Q4 ’09 Revenues in-line, fundamentals improving7$254 Stars  View Abstract
6-Nov-09Feltl & CompanyErnest W. AndbergVTAL- Q3 ’09 Seasonal increase in Toshiba sales boosts revenues and cushions loss6$254 Stars  View Abstract
5-Nov-09Feltl & CompanyErnest W. AndbergSRDX - Q4’09 Adjusted revenues and EPS below expectations7$254 Stars  View Abstract
5-Nov-09Feltl & CompanyErnest W. AndbergCSII- Q1 ’10 Revenues short of expectations, but loss and cash burn in-line6$254 Stars  View Abstract
3-Nov-09Feltl & CompanyErnest W. AndbergCSII- Q1 ’10 Preview6$254 Stars  View Abstract
3-Nov-09Feltl & CompanyErnest W. AndbergATSI- Q3 ’09 Revenues and operating loss in-line; revenue guidance maintained.7$254 Stars  View Abstract
3-Nov-09Feltl & CompanyErnest W. AndbergNAVR- Q2 ’10 Revenues down y/y, but margins and bottom line much improved7$254 Stars  View Abstract
2-Nov-09Feltl & CompanyErnest W. AndbergATSI- Q3’09 Preview6$254 Stars  View Abstract
29-Oct-09Feltl & CompanyErnest W. AndbergULGX-6$254 Stars  View Abstract
28-Oct-09Feltl & CompanyErnest W. AndbergIRIS- Q3’09 Revenue light, EPS beats by $0.02 on higher gross margin and lower expenses7$254 Stars  View Abstract
26-Oct-09Feltl & CompanyErnest W. AndbergIRIS- Q3 ’09 Earnings Preview6$254 Stars  View Abstract
23-Oct-09Feltl & CompanyErnest W. AndbergSYNO- Q3 ’09 Veritas receives CE Mark approval in Europe6$254 Stars  View Abstract
21-Oct-09Feltl & CompanyErnest W. AndbergVASC- 3Q:09 Revenue and EPS in-line; rating and price target unchanged7$254 Stars  View Abstract
19-Oct-09Feltl & CompanyErnest W. AndbergVASC- 3Q:09 Preview: Revenue and EPS should be in-line6$254 Stars  View Abstract
6-Oct-09Feltl & CompanyErnest W. AndbergSRDX- Opthalmic licensing and development agreement signed with Roche/Genentech.6$254 Stars  View Abstract
25-Mar-09Feltl & CompanyErnest W. AndbergSYNO- Bariatric surgery and diabetes5$12  View Abstract

* EPS Accuracy is a measure of an analyst's ability to accurately estimate the EPS for a company.
** Portfolio Return is a measure of the performance of an analyst's recommendations relative to his peers.

Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.